Vasculonics
Indianapolis, IN
Contact: Jaipal Singh, CSO
Vasculonics is a biotech specializing in organ protection strategies following insult from acute or chronic diseases, or trauma. The company is developing VN-1032, an oral tablet which is disease modifying for pulmonary arterial hypertension, chronic kidney disease, traumatic brain injury and vascular dementia, an extracorporeal medical device VN-901 for acute trauma and diseases with both hospital and military medicine applications. This includes sepsis, acute kidney disease, heart attack, and blast injury. Vasculonics has received great grant validation including a Catalyze grant, an SBIR phase 2a for $2.1M just starting at the end of 2024, and several Indiana grants totaling over $4.5 million in all. Vasculonics was incubated out of Indiana University and started in 2020 as a C corp.
Member Number: 218
Member Since: 2024, Basic